Background/Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized outcomes for patients with melanoma. As such, it is important to understand factors that may influence response as well as toxicity to these therapies. Impaired glucose control is often a sign of pathologic inflammation and may alter immune system regulation, but it is unclear whether glucose control impacts patients with melanoma on ICIs. Methods: After reviewing patients with melanoma treated with ICIs at our institution between 2014 and 2024, we assessed whether longitudinal glucose control is associated with patient outcomes (response, progression-free survival, overall survival, and treatment toxicity) during ICI therapy. Results: There was no significant difference in baseline glucose values between responders and non-responders (102.5 vs. 106.0,p= 0.093). Having a baseline glucose over 200 or any glucose over 200 was not significantly associated with response (p= 0.79,p= 0.20), progression-free survival (p= 0.64,p= 0.45), overall survival (p= 0.56,p= 0.36), or toxicity (p= 0.29,p= 0.11). Although a diagnosis of diabetes mellitus was not significantly associated with response (p= 0.84), progression-free survival (p= 0.12), or toxicity (p= 0.11), it was associated with improved overall survival (p= 0.0034) in the small number of patients with diabetes. Conclusions: Overall, we observed that glucose control was not strongly associated with efficacy or toxicity in patients treated with ICIs.
**背景/目的：** 免疫检查点抑制剂（ICIs）已彻底改变了黑色素瘤患者的治疗结局。因此，了解可能影响患者对这些疗法的反应及毒性的因素至关重要。血糖控制受损通常是病理性炎症的标志，并可能改变免疫系统调节，但目前尚不清楚血糖控制是否会影响接受ICIs治疗的黑色素瘤患者。 **方法：** 在回顾了2014年至2024年间于我院接受ICIs治疗的黑色素瘤患者后，我们评估了在ICI治疗期间，纵向血糖控制是否与患者结局（治疗反应、无进展生存期、总生存期及治疗毒性）相关。 **结果：** 治疗有反应者与无反应者的基线血糖值无显著差异（102.5 vs. 106.0，p=0.093）。基线血糖超过200或任何一次血糖超过200，均与治疗反应（p=0.79，p=0.20）、无进展生存期（p=0.64，p=0.45）、总生存期（p=0.56，p=0.36）或毒性（p=0.29，p=0.11）无显著相关性。尽管糖尿病诊断与治疗反应（p=0.84）、无进展生存期（p=0.12）或毒性（p=0.11）无显著相关性，但在少数糖尿病患者中，糖尿病诊断与改善的总生存期相关（p=0.0034）。 **结论：** 总体而言，我们观察到在接受ICIs治疗的患者中，血糖控制与疗效或毒性并无显著关联。
肿瘤(癌症)患者之家